Kaskela Law LLC is investigating Inotiv, Inc. (NASDAQ: NOTV) on behalf of the company’s long-term shareholders.

Recently an amended securities fraud complaint was filed against Inotiv on behalf of investors who purchased shares of the company’s stock between September 21, 2021 and November 16, 2022.  According to the complaint, during that time period Inotiv and certain of the company’s senior executive officers made a series of materially false and misleading statements and material omissions concerning “Inotiv’s acquisition of Envigo, a leading commercial provider of research animals—euphemistically referred to in the industry as “research models”—and related services, as well as false and misleading statements and material omissions concerning the company’s non-human primate-related business and the risks thereto, including but not limited to the January 2022 acquisition of Orient Bio Resource Center (‘OBRC’), a leading importer of non-human primates used in research.”

As further detailed in the complaint, following the disclosure of a series of previously concealed adverse facts, Inotiv’s stock price fell approximately 87% in value, from a price of over $55.00 per share in November 2021 to a price of $6.82 per share in November 2022.

The investigation seeks to determine whether the members of Inotiv’s board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct and disclosures.

Current Inotiv shareholders who purchased or acquired shares of NOTV stock prior to November 16, 2022 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by completing the form on this page, for additional information about this investigation and their legal rights and options.

CONTACT:

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
([email protected])
Adrienne Bell, Esq.
([email protected])
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750